omnomicsNGS

omnomicsNGS makes genome information clinically actionable using the latest research knowledge

omnomicsNGS is a cost-efficient and adaptable high-throughput genome sequencing and analysis service for the clinician. It can be used to probe patient DNA with specific human gene panels (cancer or other disease-centric testing) and also to test the entire exome or genome in complex disease cases such as cancer.

For the clinicians, it converts cutting edge knowledge from the fields of molecular biology and genomics into improved cancer treatment. The service is based on deep sequencing, integrated databases and sequence interpretation algorithms and identifies patient-/sample-, tissue- and disease-specific variations and biomarkers. The genetic variations and genome modifications are reported in the light of their effects on proteins, of their connection to diseases and to drugs. Knowledge is integrated from public and proprietary databases and regularly updated. The service is continuously developed in collaboration with oncologists and brings the latest research closer to the clinicians.

Benefits

Assists the physician in making a patient-specific diagnosis and finding actionable targets among the genetic variations
Provides important biomedical context information and better drug response predictions
Identifies individual differences in the genome and assists thus in making personalised treatment recommendations
Provides a cost-effective solution based on pricing per analysis and produces data that can be reused.
Modular: a complete turnkey solution, or an informatics service that can be integrated into an existing infrastructure.

Reference cases

Harnessing growing amounts of high-throughput sequence data for personalised healthcare
A pilot project involving public human genome annotations, protein structure, disease and drug response information has been deployed with a health care provider to evaluate new treatment methods in the context of personal medicine. This pilot project is part of a whole, presently being used for personalised healthcare development in an attempt to improve cancer prognosis, diagnosis and care.

Contact for more information

christophe.roos /a/ euformatics.com
+358 (0) 400 359 846

 

 

 

 

 

 

 

 

 

 

  • Euformatics Oy, Keilaranta 4, 02150 Espoo, Finland
© Euformatics Oy 2012